NCT06503679View on ClinicalTrials.gov

A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

July 16, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Healthy
Interventions
DRUG

LY4100511 (DC-853) Dose 1

Administered orally

DRUG

LY4100511 (DC-853) Dose 2

Administered orally

DRUG

LY4100511 (DC-853) Dose 3

Administered orally

DRUG

Midazolam

Administered orally

DRUG

Repaglinide

Administered orally

DRUG

Digoxin

Administered orally

DRUG

Rosuvastatin

Administered orally

Trial Locations (1)

75247

Fortrea Clinical Research Unit, Dallas

All Listed Sponsors
lead

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

INDUSTRY

NCT06503679 - A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants | Biotech Hunter | Biotech Hunter